Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene Therapies

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the biotech stocks to buy according to Wall Street analysts. On July 24, Rocket Pharmaceuticals announced a corporate reorganization and pipeline prioritization to maximize near-term value and extend its operational runway.

This initiative, approved by the Board of Directors on June 18, focuses the company’s resources on its adeno-associated virus/AAV cardiovascular platform and regulatory activities for KRESLADI (formerly RP-L201), its lentiviral therapy for severe leukocyte adhesion deficiency-I (LAD-I).

Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene Therapies

A pharmacist handing a customer a bottle of new anti-viral drugs utilizing DehydraTECH bio-absorption.

The restructuring involves a workforce reduction of ~30% and other cost-saving measures, which are expected to reduce Rocket’s 12-month operating expenses by ~25%. The company anticipates incurring ~$3.5 million in restructuring charges in H2 2025. With these adjustments, Rocket Pharmaceuticals expects its current cash resources, excluding any potential proceeds from a Priority Review Voucher from KRESLADI’s FDA approval, to fund operations into Q2 2027.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.

While we acknowledge the potential of RCKT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RCKT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.